ILUMYA is a humanized lgG1/okay monoclonal antibody designed to selectively bind to the p19 subunit of IL-
23 and inhibit its interplay with the IL-23 receptor, resulting in inhibition of the discharge of pro- inflammatory cytokines and chemokines.
Junichi Nakamichi, Country Head, Sun Pharma Japan, mentioned, “ILUMYA is Sun Pharma’s first innovative drug to be launched in the Japanese market. We are pleased to introduce a new, safe and effective treatment option for plaque psoriasis to doctors and patients in our country. This is an important milestone for Sun Pharma as we expand our product portfolio in Japan.”